open access

Vol 88, No 5 (2020)
Review paper
Published online: 2020-10-24
Submitted: 2020-05-19
Accepted: 2020-08-13
Get Citation

Bronchoscopic lung volume reduction using coil therapy: complications and management

Askin Gulsen
DOI: 10.5603/ARM.a2020.0152
·
Pubmed: 33169816
·
Adv Respir Med 2020;88(5):433-442.

open access

Vol 88, No 5 (2020)
REVIEWS
Published online: 2020-10-24
Submitted: 2020-05-19
Accepted: 2020-08-13

Abstract

Nonsurgical approaches involving bronchoscopic lung volume reduction (BLVR) have been developed in the last decade. One of these, the BLVR coil procedure, is a treatment option for patients with homogeneous and heterogeneous end-stage emphysema and a forced expiratory volume in 1 second (FEV1) of 15–45%. This treatment decreases hyperinflation and improves lung function, the quality of life, and exercise capacity. It is very important to prepare patients for treatment, premedications, anesthesia applications, intubation, post-procedure follow-up and treatments. Further, it has been observed that various complications can develop during and after the procedure. Generally, the observed and reported complications are chronic obstructive pulmonary disease (COPD) exacerbation, chest pain, mild bleeding, pneumonia, pneumothorax, and respiratory failure. Rarely, aspergillus cavitation (coil-related aspergilloma), bronchopleural fistula and penetration into the pleural space, bronchiectasis, coil-associated inflammatory response and opacities, and hiccups are observed. Common complications are usually mild or moderate, while the rare ones can be life-threatening (except hiccup), so early diagnosis and treatment are necessary. However, patients treated with BLVR have lower mortality rates than untreated patients with similar morbidity. Based on the findings of this review, we can estimate that premedication one day before and just before the procedure may reduce potential complications. Some medical centers apply and recommend 30-day macrolide treatment after the procedure. New generation supraglottic devices may be preferred to avoid complications due to endotracheal intubation. Moreover, further research is needed to identify risk factors, prevent potential complications, and a common consensus is required for routine preventive treatment.

Abstract

Nonsurgical approaches involving bronchoscopic lung volume reduction (BLVR) have been developed in the last decade. One of these, the BLVR coil procedure, is a treatment option for patients with homogeneous and heterogeneous end-stage emphysema and a forced expiratory volume in 1 second (FEV1) of 15–45%. This treatment decreases hyperinflation and improves lung function, the quality of life, and exercise capacity. It is very important to prepare patients for treatment, premedications, anesthesia applications, intubation, post-procedure follow-up and treatments. Further, it has been observed that various complications can develop during and after the procedure. Generally, the observed and reported complications are chronic obstructive pulmonary disease (COPD) exacerbation, chest pain, mild bleeding, pneumonia, pneumothorax, and respiratory failure. Rarely, aspergillus cavitation (coil-related aspergilloma), bronchopleural fistula and penetration into the pleural space, bronchiectasis, coil-associated inflammatory response and opacities, and hiccups are observed. Common complications are usually mild or moderate, while the rare ones can be life-threatening (except hiccup), so early diagnosis and treatment are necessary. However, patients treated with BLVR have lower mortality rates than untreated patients with similar morbidity. Based on the findings of this review, we can estimate that premedication one day before and just before the procedure may reduce potential complications. Some medical centers apply and recommend 30-day macrolide treatment after the procedure. New generation supraglottic devices may be preferred to avoid complications due to endotracheal intubation. Moreover, further research is needed to identify risk factors, prevent potential complications, and a common consensus is required for routine preventive treatment.

Get Citation

Keywords

bronchoscopic; lung volume reduction; coil; complication; management

About this article
Title

Bronchoscopic lung volume reduction using coil therapy: complications and management

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 5 (2020)

Article type

Review paper

Pages

433-442

Published online

2020-10-24

DOI

10.5603/ARM.a2020.0152

Pubmed

33169816

Bibliographic record

Adv Respir Med 2020;88(5):433-442.

Keywords

bronchoscopic
lung volume reduction
coil
complication
management

Authors

Askin Gulsen

References (51)
  1. Minai OA, Benditt J, Martinez FJ. Natural history of emphysema. Proc Am Thorac Soc. 2008; 5(4): 468–474.
  2. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 Guideline. Available at:https://goldcopd.org/wp-content/uploads/2020/03/GOLD-2020-POCKET-GUIDE-ver1.0_FINAL-WMV.pdf. [Last accessed at: 04.08.2020].
  3. Altintas N. Update: non-invasive positive pressure ventilation in chronic respiratory failure due to COPD. COPD. 2016; 13(1): 110–121.
  4. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014 — an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015; 34(1): 1–15.
  5. Lammi MR, Marchetti N, Barnett S, et al. Heterogeneity of lung volume reduction surgery outcomes in patients selected by use of evidence-based criteria. Ann Thorac Surg. 2013; 95(6): 1905–1911.
  6. Decker MR, Leverson GE, Jaoude WA, et al. Lung volume reduction surgery since the National Emphysema Treatment Trial: study of Society of Thoracic Surgeons Database. J Thorac Cardiovasc Surg. 2014; 148(6): 2651–8.e1.
  7. Gülşen A. Bronchoscopic lung volume reduction: a 2018 review and update. Turk Thorac J. 2018; 19(3): 141–149.
  8. Ramaswamy A, Puchalski J. Bronchoscopic lung volume reduction: recent updates. J Thorac Dis. 2018; 10(4): 2519–2527.
  9. Ramaswamy A, Puchalski J. Bronchoscopic lung volume reduction: recent updates. Journal of Thoracic Disease. 2018; 10(4): 2519–2527.
  10. Herth FJF, Slebos DJ, Criner GJ, et al. Endoscopic lung volume reduction: an expert panel recommendation — update 2019. Respiration. 2019; 97(6): 548–557.
  11. Welling JBA, Slebos DJ. Lung volume reduction with endobronchial coils for patients with emphysema. J Thorac Dis. 2018; 10(Suppl 23): S2797–S2805.
  12. Arevalo-Ludeña J, Arcas-Bellas JJ, Alvarez-Rementería R, et al. A comparison of the I-Gel supraglottic device with endotracheal intubation for bronchoscopic lung volume reduction coil treatment. J Clin Anesth. 2016; 31: 137–141.
  13. Yu SH, Beirne OR. Laryngeal mask airways have a lower risk of airway complications compared with endotracheal intubation: a systematic review. J Oral Maxillofac Surg. 2010; 68(10): 2359–2376.
  14. Grande B, Loop T. Anaesthesia management for bronchoscopic and surgical lung volume reduction. J Thorac Dis. 2018; 10(Suppl 23): S2738–S2743.
  15. Gulsen A, Sever F, Girgin P, et al. Evaluation of bronchoscopic lung volume reduction coil treatment results in patients with severe emphysema. Clin Respir J. 2017; 11(5): 585–592.
  16. Slebos DJ, Klooster K, Ernst A, et al. Bronchoscopic lung volume reduction coil treatment of patients with severe heterogeneous emphysema. Chest. 2012; 142(3): 574–582.
  17. Shah P, Zoumot Z, Singh S, et al. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. The Lancet Respiratory Medicine. 2013; 1(3): 233–240.
  18. Klooster K, Ten Hacken NHT, Franz I, et al. Lung volume reduction coil treatment in chronic obstructive pulmonary disease patients with homogeneous emphysema: a prospective feasibility trial. Respiration. 2014; 88(2): 116–125.
  19. Deslee G, Klooster K, Hetzel M, et al. Lung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial. Thorax. 2014; 69(11): 980–986.
  20. Hartman JE, Klooster K, Gortzak K, et al. Long-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema. Respirology. 2015; 20(2): 319–326.
  21. Zoumot Z, Kemp SV, Singh S, et al. Endobronchial coils for severe emphysema are effective up to 12 months following treatment: medium term and cross-over results from a randomised controlled trial. PLoS One. 2015; 10(4): e0122656.
  22. Deslée G, Mal H, Dutau H, et al. Lung volume reduction coil treatment vs usual care in patients with severe emphysema: the REVOLENS randomized clinical trial. JAMA. 2016; 315(2): 175–184.
  23. Sciurba FC, Criner GJ, Strange C, et al. Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema: the RENEW randomized clinical trial. JAMA. 2016; 315(20): 2178–2189.
  24. Kontogianni K, Gerovasili V, Gompelmann D, et al. Coil therapy for patients with severe emphysema and bilateral incomplete fissures — effectiveness and complications after 1-year follow-up: a single-center experience. Int J Chron Obstruct Pulmon Dis. 2017; 12: 383–394.
  25. Simon M, Harbaum L, Oqueka T, et al. Endoscopic lung volume reduction coil treatment in patients with very low FEV: an observational study. Ther Adv Respir Dis. 2018; 12: 1753466618760133.
  26. Simon M, Ittrich H, Harbaum L, et al. Bleeding complications after endoscopic lung volume reduction coil treatment: a retrospective observational study. Arch Bronconeumol. 2016; 52(12): 590–595.
  27. Dutau H, Bourru D, Guinde J, et al. Successful late removal of endobronchial coils. Chest. 2016; 150(6): e143–e145.
  28. Valipour A, Slebos DJ, de Oliveira HG, et al. Expert statement: pneumothorax associated with endoscopic valve therapy for emphysema — potential mechanisms, treatment algorithm, and case examples. Respiration. 2014; 87(6): 513–521.
  29. Slebos DJ, Hartman JE, Klooster K, et al. Bronchoscopic coil treatment for patients with severe emphysema: a meta-analysis. Respiration. 2015; 90(2): 136–145.
  30. Orton CM, Garner JL, Desai SR, et al. Aspergillus cavitation complicating endobronchial lung volume reduction coil placement. Am J Respir Crit Care Med. 2020; 201(3): e8–e9.
  31. Plante A, Guinde J, Boudreau C, et al. A rare complication: development of an aspergilloma after endobronchial coil placement in a COPD patient. Respiration. 2020; 99(5): 423–425.
  32. Gulsen A, Sever F, Girgin P, et al. Bronchopleural fistula and pneumothorax following lung volume reduction coil treatment in severe emphysema: A case report. 1.4 Interventional Pulmonology. 2015.
  33. Mongelli F, Cafarotti S, Di Giuseppe M, et al. Late onset of pneumothorax after bronchoscopic lung volume reduction due to migration of a nitinol coil. Eur J Cardiothorac Surg. 2018; 53(4): 884–885.
  34. Marchetti G, McCracken DJ, Rahman NM. Endobronchial coil penetration into the pleural space. Thorax. 2018; 73(9): 890–891.
  35. Franzen D, Straub G, Freitag L. Complications after bronchoscopic lung volume reduction. J Thorac Dis. 2018; 10(Suppl 23): S2811–S2815.
  36. Debray MP, Marceau A, Dombret MC, et al. Bronchiectasis complicating lung volume reduction coil treatment. Chest. 2017; 152(3): e57–e60.
  37. Herth FJF, Eberhardt R, Ingenito EP, et al. Assessment of a novel lung sealant for performing endoscopic volume reduction therapy in patients with advanced emphysema. Expert Rev Med Devices. 2011; 8(3): 307–312.
  38. Kramer MR, Refaely Y, Maimon N, et al. Bilateral endoscopic sealant lung volume reduction therapy for advanced emphysema. Chest. 2012; 142(5): 1111–1117.
  39. Gompelmann D, Eberhardt R, Ernst A, et al. The localized inflammatory response to bronchoscopic thermal vapor ablation. Respiration. 2013; 86(4): 324–331.
  40. Michaud GC, Carbone C, Sciurba FC, et al. Coil associated inflammatory response syndrome (CAIRS) following endoscopic lung volume reduction with endobronchial coils in severe emphysema. Am J Respir Crit Care Med. 2018; 197: A1726.
  41. Perch M, Johannesen H, Fiehn AM, et al. The “coil associated opacity” in endoscopic emphysema treatment. Friend or foe? Interventional Pulmonology. 2018.
  42. Kayani K, Mahadeva R, Stinchcombe S, et al. Lung function improvements in emphysema following pneumonia. Respir Med Case Rep. 2019; 26: 1–5.
  43. van Hirtum PV, Sprooten RTM, van Noord JA, et al. Long term survival after admission for COPD exacerbation: A comparison with the general population. Respir Med. 2018; 137: 77–82.
  44. Martinez FJ, Foster G, Curtis JL, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med. 2006; 173(12): 1326–1334.
  45. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014 — an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015; 34(1): 1–15.
  46. Grewal HS, Mehta AC. Emphysema management: from investigational endobronchial coils to lung transplantation. Am J Respir Crit Care Med. 2018; 198(3): e14.
  47. Gulsen A. Importance of bronchoscopic lung volume reduction coil therapy in potential candidates for lung transplantation. Biosci Trends. 2018; 12(4): 395–402.
  48. Trudzinski FC, Seiler F, Wilkens H, et al. Microbiological airway colonization in COPD patients with severe emphysema undergoing endoscopic lung volume reduction. Int J Chron Obstruct Pulmon Dis. 2018; 13: 29–35.
  49. Casutt A, Koutsokera A, Lovis A. Lung volume reduction coil treatment: is there an indication for antibiotic prophylaxis? Arch Bronconeumol. 2016; 52(2): 114–115.
  50. Ohtsu N, Suginishi S, Hirano M. Antibacterial effect of nickel-titanium alloy owing to nickel ion release. Applied Surface Science. 2017; 405: 215–219.
  51. Stoppel R, Schlegel HG. Nickel-resistant bacteria from anthropogenically nickel-polluted and naturally nickel-percolated ecosystems. Appl Environ Microbiol. 1995; 61(6): 2276–2285.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl